Compare 8x8 Inc (EGHT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Gilead Sciences, Inc. — how do they compare? 8x8 Inc trades at $2.1 (market cap $288.87M), while Gilead Sciences, Inc. trades at $138.44 (market cap $168.47B). The key difference: Gilead Sciences, Inc. is far larger — about 583.2× 8x8 Inc's market cap, and Gilead Sciences, Inc. pays a 2.41% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | GILD | |
|---|---|---|
Market Cap | $288.87M | $168.47B |
Sector | Technology | Health |
52-Week High | $2.76 | $155.80 |
52-Week Low | $1.59 | $110.56 |
Enterprise Value | $555.80M | $191.54B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.01, down 6.07% today, with a neutral technical signal. The company reported a net loss of $27.21M for 2025 despite revenue of $715.07M, but recent quarters show earnings beats. Analyst consensus is a $3.13 price target with a mixed buy/hold sentiment. Positive developments include AI product expansions and a new partner program aimed at growth.
The outlook hinges on execution toward profitability; projected 2026 net income of $5M offers optimism, but high debt and thin margins pose risks. The stock presents a speculative opportunity if operational improvements continue, though volatility and competitive pressures remain key concerns for investors.
Gilead Sciences (GILD) trades at $138.14, up 1.75% in the last session, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q2 2026 revenue growth of 8% year-over-year, driven by HIV drug sales, though a net loss of $6.75 per share resulted from acquisition-related charges. Analyst consensus is strongly bullish with a $151.22 price target, while institutional activity shows mixed positioning adjustments.
The outlook for GILD is positive due to robust HIV franchise performance and raised 2026 guidance, but risks include patent cliffs by the mid-2030s and integration costs from acquisitions. The stock offers potential upside from pipeline advancements, though volatility may persist from earnings fluctuations and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
